Table 1.
Demographic and clinical characteristics of participants
| Status | TB+HIV+ | TB+HIV− | AIDS/HIV+ | HIV− Controls |
|---|---|---|---|---|
| Number of subjects analyzed | 7 | 20 | 17 | 28 |
| Mean age in y ± SE | 38 ± 2 | 32 ± 3 | 39 ± 5 | 43 ± 4 |
| Sex | 6 males, 1 female | 14 males, 6 females | 12 males, 5 females | 21 males, 7 females |
| Ethnicity | ||||
| North Africans | 1 | 2 | 2 | 2 |
| Caucasians Western Europe | 5 | 12 | 11 | 21 |
| Caucasians Eastern Europe | — | 2 | 1 | 3 |
| Asian | — | 1 | — | 2 |
| South Americans | 1 | 3 | 3 | — |
| BCG vaccination | 1 | 5 | 7 | 9 |
| Localization of TB | ||||
| Pulmonary | 5 | 12 | — | — |
| Extrapulmonary | 1 | 5 | — | — |
| Pulmonary and extrapulmonary | 1 | 3 | — | — |
| HIV-RNA (copies/mL) ± SE | 46330 ± 17260 | — | 33390 ± 11120 | — |
| Mean CD4 cell number/μL ± SE | 238 ± 86 | 713 ± 94 | 321 ± 56 | 1121 ± 101 |
| HAART | 5 | — | 5 | — |
HAART, highly active antiretroviral therapy.